—
C+
C+ The full Closelook — membership. Open the C+ overview

Orion Oyj A (ORNAV.HE) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Orion Oyj A

ORNAV.HE in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Orion Oyj develops, makes and markets prescription medicines, active pharmaceutical ingredients and veterinary drugs, and sells self-care products such as vitamins and skincare. Its prescription range spans prostate cancer, Parkinson's disease, asthma and COPD inhalers, pain relief and menopausal treatments, sold across Finland, Scandinavia and wider international markets. It also manufactures compounds for other drugmakers under contract and licenses some of its own molecules to partner companies. Orion is based in Espoo, Finland.
Where it sits in the stack
Orion carries no seat in our index and sits outside the Rubin build-out framework; it belongs to the Healthcare sector of our universe, under Drug Manufacturers - General, as a diversified pharmaceutical maker rather than a supplier into any technology stack.
Who it is priced against
Closelook's peer group has no entry for Orion; the market usually sets it alongside other Nordic pharmaceutical makers, with Novo Nordisk as the name most often named in comparison.
Why Closelook tracks it
Orion carries a Closelook score, but only one module is scored so far, so the read is still being built; it holds no index seat and has not drawn a diary mention.
What the diary watches
Whether newer prescription products, including the licensed prostate cancer treatment, keep growing enough to offset pressure on older drugs as patents and competition catch up.

Orion Oyj A (ORNAV.HE) trades on the HE exchange in Finland, classified under Healthcare.

The Closelook company score reads 62/100 composite (momentum 78, quality 83, valuation 34) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for ORNAV.HE, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Drug Manufacturers - General · 8 names with week and year-to-date

Peer group

Drug Manufacturers - General

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against ORNAV.HE on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return trailing yield 2.11%, semi-annual · last 0.90 EUR on 2026-03-25

Dividends and capital return

What ORNAV.HE pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 1.72 EUR per share · a 2.11% yield on the 2026-09-18 close 2 distributions, paid twice a year 2026-09-18
  • Change on the year +109.7% against the prior twelve months prior twelve months 0.82 EUR per share
  • Last distribution 0.90 EUR per share as the price series records it, within days of the ex-date 2026-03-25
  • By calendar year 2025: 1.64 EUR (partial) · 2026: 0.90 EUR to date first distribution recorded in the three-year window: 2025-04-04
  • Dividends paid, FY2025 231 m EUR 41% of earnings
  • Share count +0.1% in FY2025
  • Capital returned 231 m EUR · 105% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sector × region Health care in Europe: +3.0% week · −4.5% month · −2.1% quarter · −5.0% yearThe Sector Engine cell this name lives in, from EXV4.XETRA; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-20
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Orion Oyj A (ORNAV.HE)?

Orion Oyj A trades as ORNAV.HE on the HE exchange (Finland) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-19.

Is ORNAV.HE in a Closelook index?

Not currently — Orion Oyj A is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

What is Orion Oyj A's Closelook composite score?

62 out of 100, with momentum 78, quality 83 and valuation 34 sub-scores, as of 2026-09-19. Scores are Closelook's own research readings, not ratings or investment advice.

Where does ORNAV.HE trade against its moving averages?

Uptrend stack intact: Trades +3.9% vs the 50-day and +15.5% vs the 200-day average, 1.6% below the 52-week high and +46.5% off the 52-week low. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Orion Oyj A do?

Orion Oyj develops, makes and markets prescription medicines, active pharmaceutical ingredients and veterinary drugs, and sells self-care products such as vitamins and skincare. Its prescription range spans prostate cancer, Parkinson's disease, asthma and COPD inhalers, pain relief and menopausal treatments, sold across Finland, Scandinavia and wider international markets. It also manufactures compounds for other drugmakers under contract and licenses some of its own molecules to partner companies. Closelook's peer group has no entry for Orion; the market usually sets it alongside other Nordic pharmaceutical makers, with Novo Nordisk as the name most often named in comparison.

Where does Orion Oyj A sit in the AI build-out?

Orion carries no seat in our index and sits outside the Rubin build-out framework; it belongs to the Healthcare sector of our universe, under Drug Manufacturers - General, as a diversified pharmaceutical maker rather than a supplier into any technology stack. Orion carries a Closelook score, but only one module is scored so far, so the read is still being built; it holds no index seat and has not drawn a diary mention.

Does Orion Oyj A pay a dividend?

Orion Oyj A has paid 1.72 EUR per share over the last twelve months, paid twice a year, a trailing yield of 2.11% on the 2026-09-18 close; the last distribution recorded in the price series was 0.90 EUR on 2026-03-25. In fiscal 2025 the company paid 231 m EUR in dividends, 105% of that year’s free cash flow. The share count rose 0.1% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for ORNAV.HE, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.